Lisa shared her personal metabolic protocol — not as medical advice, but to showcase alternatives to DON for glutamine inhibition, plus a detailed food/activity journal and drug sensitivity testing (Onconomics Plus by RGCC). She based her decisions on lab results to guide which drugs and nutraceuticals to include or omit. ✅ Scientific & Philosophical Insights - Focus on Press-Pulse strategy: combining glucose/glutamine inhibition, fasting, HBOT, and nutraceuticals. - Belief that cancer is a mitochondrial metabolic disease, not a genetic one. - Lisa emphasized practical implementation in the real world, not theoretical models. - Her journal tracked macros, GKI, energy, and treatment timing to optimize synergy. ✅ Practical Wisdom from Community - Egg Scrambled suggested R-ALA instead of ALA, and Pterostilbene instead of Resveratrol for better bioavailability. - Discussion on 2DG as a glucose blocker before HBOT. - Stephen Mecke recommended sulforaphane for prostate and other cancers — highlighted enzyme myrosinase importance and shared links. - Mi Mo commented on CTC trends and her own carnivore experience. - Lisa’s non-negotiables include keto macros, fasting windows, sleep schedule, and daily rebounding/earthing. ✅ Resources & References Shared - Lisa’s Onconomics Plus RGCC Report (CTC: 2.2 cells/ml). - Supplements purchased from Chemist Warehouse, iHerb, NutriNZ, Bob Harrison Dispensary, Poten-C NZ, MCSFormulas. - Research links on: • Ketogenic diet • Glutamine metabolism • ReDO protocol • Vitamin C, Quercetin, Curcumin, HBOT • Earthing, Contrast Therapy, Apoptosis markers ✅ Key Takeaways - Lisa’s protocol includes over 30 nutraceuticals, 10+ repurposed drugs, HBOT, fasting, and infrared therapy. - Glutamine inhibitors used: Fenbendazole, Sodium Phenylbutyrate, Dipyridamole, Loratadine, Ursolic Acid, Hesperidin, EGCG — as DON alternatives. - IV Vitamin C, Capecitabine, DCA, Metformin, Cimetidine, and Propranolol all included based on test sensitivity. - Daily lifestyle factors (sleep, fasting, movement, rebounder, tracking GKI) treated as core therapies, not extras. - This protocol is a strong case study in patient-led, test-informed, multi-modal metabolic therapy.

Lisa shared her MRI results after a three-week experimental protocol combining dry fasting and Hyperbaric Oxygen Therapy (HBOT). Out of the three weeks, she dry fasted for a total of 11 days (mostly in 2–3 day blocks followed by refeeding). While the tumour was not fully eliminated, there was a further reduction in mass compared to previous imaging (no exact measurements provided). Lymph nodes remain clear, and there has been no disease progression despite periods of dietary non-compliance. Lisa notes that extended fasting is often cited as necessary to fully trigger autophagy and cell cannibalism, but as she is very lean, she limits fasts to 4 days maximum before refeeding. She also suspects tumour resistance factors, such as MDR1 overexpression, may play a role in limiting impact. ✅ Supplements & Compounds - No specific compounds during fasting phase; paused ReDO protocol drugs to give the liver a rest - Normally uses ReDO Project repurposed drugs in her broader protocol - Will consider reintroducing supplements and off-labels after returning from travel ✅ Therapies & Strategies - Dry fasting – 11 days total over 3 weeks (in 2–3 day blocks) - HBOT – multiple sessions during the 3-week period - Refeeding phases between fasts for weight and energy recovery - Travel and sun exposure during protocol break in Florida - Considering next-stage protocol adjustments after weight and muscle recovery ✅ Lab Testing & Monitoring - MRI – confirmed tumour mass reduction (degree unspecified) and no lymph node involvement - Subjective monitoring of energy levels, muscle mass, and weight ✅ Resources & References Shared - MDR1 overexpression research in relation to tumour resistance - ReDO Project information on repurposed cancer drugs - Peer discussion on GKI, MCT oil, exogenous ketones, protein balance, and muscle rebuilding strategies ✅ Key Takeaways - Even short fasting cycles combined with HBOT may contribute to tumour reduction and stability. - Maintaining sufficient body mass is critical when fasting, especially for already lean individuals. - MDR1 overexpression may limit the effects of certain metabolic interventions, warranting tailored strategies. - Pausing certain drugs or supplements during fasting may help protect organ function but could impact protocol potency. - Ongoing experimentation, testing, and adaptation remain central to Lisa’s approach.

Melissa was diagnosed in January 2024 with breast cancer and bone metastasis affecting the vertebrae, sacrum, iliac crest, and ribs. She began standard treatment with Kisqali (ribociclib) and Letrozole, followed by 10 sessions of radiotherapy, which greatly reduced pain and improved mobility. In May 2024, she added metabolic therapy to her approach, adjusting diet, integrating repurposed drugs, targeted supplements, and lifestyle changes. In June 2025, a PET scan revealed no hypermetabolism — indicating no visible tumors (NED). Melissa continues her protocols to maintain results. ✅ Supplements & Compounds Core agents used in her integrative approach: - Fenbendazole (Joe Tippens protocol) - CBD oil - Metformin – 1700 mg/day (split into 2 doses) - Dapagliflozin – 10 mg/day - Intravenous Vitamin C – up to 0.25 g/kg per session (titrated to tolerance) - Green tea infusion – daily - Turmeric – homegrown, daily useDietary approach: - Ketogenic diet targeting GKI of 2 (modified over time to ~3–3.5 for energy balance) - Low carb (10–30g/day) from vegetables: broccoli, mushrooms, spinach, onion, garlic - Protein: 1–1.5 g/kg body weight - Fat: ~4x protein intake - Whole foods; avoids processed or “barcode” foods ✅ Therapies & Strategies - Hyperbaric Oxygen Therapy (HBOT) – 20 sessions - Radiotherapy – 10 sessions (initial pain relief and mobility restoration) - Keto metabolic strategy – sustained long-term dietary adherence - Sunlight exposure – daily in tropical climate - Gradual protocol adjustment – modified macros to prevent excess weight loss - Considered but did not use: DON, CDA, 2DG (due to existing progress) ✅ Lab Testing & Monitoring - PET scan – confirmed NED in June 2025 - No detailed tumor marker data shared, but progression tracked via imaging - Self-monitoring of GKI for metabolic tracking ✅ Resources & References Shared - Joe Tippens Protocol (fenbendazole + CBD) - Dr. Beckman’s “barcode food” concept - GKI tracking resources for ketogenic therapy - Community encouragement and peer support throughout journey

Lisa Drake shared an impressively structured and deeply honest update on her 7-week experimental protocol, reporting further tumour mass reduction but not yet full remission. While initial tumour volume was measured at 2900mm³, recent scans provided only partial dimensions or vague terms like “stable” or “slightly reduced,” making accurate tracking difficult. Lisa now estimates the remaining tumour is between 0.8–1.2cm. Her protocol blended repurposed drugs, targeted supplements, intense fasting, metabolic strategies, and emotional healing. Despite occasional lapses, Lisa’s progress, resilience, and self-awareness drew wide admiration from the community. ✅ Key Protocol Components Shared Cycle structure: - 2 weeks on: Full drug + supplement protocol - 1 week off: Alternate days of dry fasting and keto - Repeat - Final off week: 4 days dry fast (no food/water/showering) + 3 days water-only fast Morning: - Matcha + dandelion + soursop tea - Liquid Kurk (bioavailable curcumin – 20% Onconomics sensitivity) - Capecitabine (2x 500mg – 81%) - Frankincense Carterii (3x 500mg – 25%) - Genistein (3x 125mg – 25%) - Quercetin (3x 500mg – 30%) - Agaricus blazei (3x) - Sodium Phenylbutyrate (4x 500mg – glutamine antagonist) Lunch (keto/carnivore): - Fenbendazole - Propranolol - Cimetidine - Loratadine - Dipyridamole - Metformin - Naltrexone - Celebrex - Sodium Phenylbutyrate Dinner: - Repeat morning/afternoon stack - Capecitabine taken only when protein intake is high ✅ Scientific & Philosophical Insights - Imaging inconsistencies raised questions about how to accurately measure tumour change over time. - Use of the Onconomics test to personalize supplement selection shows the value of precision-guided therapy. - Acknowledged that 7 weeks may not have been enough — 12 weeks is a more realistic window for response. - Lisa is considering shifting from attack mode (blocking pathways) to a deeper focus on gut healing and system balance, reflecting a philosophical evolution in her healing journey. - Deep insights into how gut health, trauma history, and mental health can act as barriers to progress — especially with a 20-year history of bulimia and occasional lapses.

Stuart Briscoe shared a powerful case from Dr. William Makis, describing a Canadian patient with Stage 4 melanoma and extensive liver metastases who was told he had just 2–3 days to live. The patient’s liver was “completely taken over” with cystic and solid lesions, yet he began a regimen of ivermectin, fenbendazole, and mebendazole — and within two months, most metastases had shrunk or disappeared. The post sparked a multi-layered discussion — from dosing details and brand preferences to broader conversations about the clash between “evidence-based medicine” and the lived experiences of patients seeking alternative protocols. ✅ Key Protocol Components Shared - Makis Clinic Protocol (used in the case): - Stuart explained he splits his doses into smaller amounts across the day to maintain peak serum levels for longer. - Discussion about titrating doses — starting higher (some patients reportedly used up to 2.5mg/kg ivermectin) until scans showed regression, then tapering. - Mention of mixing fenbendazole with fats (yogurt, olive oil, butter) to boost absorption. - Brand considerations: Stuart likes US-manufactured tablets but rotates between FenBenLab, Wormentel, and Indian sources, echoing Dr. Makis’ recommendation to mix brands. ✅ Scientific & Philosophical Insights - Stuart framed the case as proof against the claim that fenbendazole damages the liver — pointing out that it was used successfully in a patient with liver failure. - John Brebeuf Garcia voiced frustration with medical professionals at MD Anderson who dismiss ivermectin, fenbendazole, and mebendazole as “not evidence-based,” noting how these attitudes can drain hope and energy from patients exploring alternatives. - This led to a deeper philosophical exchange: - The discussion even touched on faith and humility — “no atheists in a foxhole” — with several members noting how life-threatening illness often deepens spiritual reflection. ✅ Practical Wisdom from Community - Absorption & dosing tips: Splitting doses, taking fenbendazole with fats, and rotating brands to avoid reliance on one supplier. - Quality checks: Members suggested reading Amazon reviews and mixing manufacturers based on Dr. Makis’ clinical guidance.